D.R. Horton
DHI
Lennar Corp
LEN
KB Home
KBH
4
Petroleo Brasileiro SA Petrobras
PBR
5
Ecopetrol
EC
US Stock MarketDetailed Quotes
CPRX Catalyst Pharmaceuticals
- 20.670
- -1.290-5.87%
Close Mar 10 16:00 ET
- 20.600
- -0.070-0.34%
Pre 08:41 ET
2.51BMarket Cap15.78P/E (TTM)
21.674High20.620Low1.25MVolume21.520Open21.960Pre Close26.00MTurnover1.10%Turnover Ratio15.78P/E (Static)121.45MShares24.64052wk High3.45P/B2.35BFloat Cap14.47052wk Low--Dividend TTM113.80MShs Float24.640Historical High--Div YieldTTM4.80%Amplitude0.370Historical Low20.867Avg Price1Lot Size
About Catalyst Pharmaceuticals Company
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Company Profile
SymbolCPRX
Company NameCatalyst Pharmaceuticals
Listing DateNov 8, 2006
Issue Price6.00
Founded2002
CEOMr. Richard J. Daly
MarketNASDAQ
Employees167
Fiscal Year Ends12-31
Address355 Alhambra Circle,Suite 801
CityCoral Gables
ProvinceFlorida
CountryUnited States of America
Zip Code33134
Phone1-305-420-3200
Company Executives
- Name
- Position
- Salary
- Richard J. Daly
- Director, President and Chief Executive Officer
- 14.08M
- Michael W. Kalb
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Jeffrey Del Carmen
- Executive Vice President and Chief Commercial Officer
- 2.51M
- Dr. Steven R. Miller,PhD
- Executive Vice President, Chief Operating Officer and Chief Scientific Officer
- 3.40M
- Dr. Preethi Sundaram, PhD
- Chief Strategy Officer
- --
- Brian Elsbernd, J.D.
- Chief Compliance Officer and Chief Legal Officer
- --
- Dr. Gary Ingenito,M.D.,PhD
- Chief Medical and Regulatory Officer
- 2.37M
- Patrick J. McEnany
- Non-Executive Chairman of the Board
- 2.15M
- Charles B. O'Keeffe
- Lead Independent Director
- 397.24K
- Molly Harper
- Independent Director
- 363.12K
- Tamar Thompson
- Independent Director
- 610.43K
- Donald A. Denkhaus
- Independent Director
- 376.24K
- Dr. David S. Tierney,M.D.
- Independent Director
- 370.99K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025